CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

CENTOGENE to perform epidemiology study in Alpha Mannosidosis to support Chiesi’s drug discovery and development

The College of American Pathologists (CAP), a Center for Medicare and Medicaid Services (CMS)-approved accreditation authority, has awarded CENTOGENE…

Provides physicians with virtual encyclopedia of genetic information at their fingertips for improved and efficient diagnosis of rare diseases

CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2…

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform

We are proud to have been honored with the award from the Federal State Government of Mecklenburg-Vorpommern in the category ‘Company Development’. We…

CENTOGENE announced today a partnering with the Medical Faculties of the Universities of Greifswald and Rostock for the research project, “Development…

CENTOGENE announced today the opening of its first U.S. based rare disease laboratory in Cambridge, Massachusetts. The new facility, opening on August…

CENTOGENE, driving the diagnostic workflows and individualized therapeutic decisions not only in rare diseases but also in oncological setups is proud…

CENTOGENE, the worldwide leader in using genetic and proteomic knowledge to enable patients, clinicians and pharmaceutical partners to identify and…

For Further Inquiries Please Contact

Press Contact

Ben Legg

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads